<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89323-0087 </DOCNO><DOCID>fr.3-23-89.f2.A1086</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="52">Advisory Committees; Meetings</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>This notice announces forthcoming meetings of publicadvisory committees of the Food and Drug Administration (FDA). This noticealso summarizes the procedures for the meetings and methods by which interestedpersons may participate in open public hearings before FDA's advisory committees.<T3>Meetings: </T3>The following advisory committee meetings are announced:<ITAG tagnum="84">Vaccines and Related Biological Products Advisory Committee</ITAG><T3>Date, time, and place. </T3>April 7, 1989, 8:15 a.m., Parklawn Bldg.,Conference Rms. D and E, 5600 Fishers Lane, Rockville, MD.<T3>Type of meeting and contact person. </T3>Open committee discussion,April 7, 1989, 8:15 a.m. to 10:50 a.m.; closed committee deliberations,10:50 a.m. to 11:20 a.m.; open public hearing, 11:20 a.m. to 12:20 p.m.,unless public participation does not last that long; closed committee deliberations,1:15 p.m. to 2:15 p.m.; open committee discussion, 2:15 p.m. to 4:15 p.m.;Jack Gertzog, Center for Drug Evaluation and Research (HFD-9), Food andDrug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.<T3>General function of the committee. </T3>The committee reviews and evaluatesavailable data on the safety and effectiveness of marketed and investigationalhuman drugs for use in the diagnosis, prevention, or treatment of humandiseases. The committee also reviews and evaluates the quality and relevanceof FDA's research program which provides scientific support for the regulationof these products.<T3>Agenda_Open public hearing. </T3>Interested persons may present data,information, or views, orally or in writing, on issues pending before thecommittee. Those desiring to make formal presentations should notify thecontact person before March 24, 1989, and submit a brief statement of thegeneral nature of the evidence or arguments they wish to present, the namesand addresses of proposed participants, and an indication of the approximatetime required to make their comments.<T3>Open committee discussion. </T3>The committee will discuss a pendingtreatment investigational new drug application (IND) for IMREG-I.<T3>Closed committee deliberations. </T3>The committee will review tradesecret or confidential commercial information relevant to the pending IND.This portion of the meeting will be closed to permit discussion of thisinformation (5 U.S.C. 552b(c)(4)). Seating is limited and the public willbe accommodated on a first come, first serve, basis.<ITAG tagnum="84">Ophthalmic Devices Panel</ITAG><T3>Date, time, and place. </T3>April 13 and 14, 1989, 9 a.m., Auditorium,Hubert H. Humphrey Bldg., 200 Independence Ave. SW., Washington, DC.<T3>Type of meeting and contact person. </T3>Open public hearing, April13, 1989, 9 a.m., to 10 a.m., unless public participation does not lastthat long; open committee discussion, 10 a.m. to 3 p.m.; closed committeedeliberations, 3 p.m. to 4 p.m.; open committee discussion, 4 p.m. to 5p.m.; open public hearing, April 14, 1989, 9 a.m. to 10 a.m., unless publicparticipation does not last that long; open committee discussion, 10 a.m.to 3 p.m.; closed committee deliberations, 3 p.m. to 4 p.m.; open committeediscussion, 4 p.m. to 5 p.m.; Daniel W. C. Brown, Center for Devices andRadiological Health (HFZ-460), Food and Drug Administration, 8757 GeorgiaAve., Silver Spring, MD 20910, 301-427-7320.<T3>General function of the committee. </T3>The committee reviews and evaluatesavailable data on the safety and effectiveness of devices currently inuse and makes recommendations for their regulation. The committee alsoreviews data on new devices and makes recommendations regarding their safetyand effectiveness and their suitability for marketing.<T3>Agenda_Open public hearing. </T3>Interested persons may present data,information, or views, orally or in writing, on issues pending before thecommittee. Those desiring to make formal presentations should notify thecontact person before March 21, 1989, and submit a brief statement of thegeneral nature of the evidence or arguments they wish to present, the namesand addresses of proposed participants, and an indication of the approximatetime required to make their comments.<T3>Open committee discussion. </T3>On April 13, 1989, the committee willdiscuss general issues relating to approvals of premarket approval applications(PMA's) for intraocular lenses (IOL's) and other class III surgical ordiagnostic devices, and may discuss specific PMA's for these devices. Ifdiscussion of all pertinent IOL or other class III surgical or diagnosticdevice issues are not completed, discussion will be continued the followingday. On April 14, 1989, the committee will discuss PMA's for contact lensesand other devices and requirements for PMA approval.<T3>Closed committee deliberations. </T3>The committee may discuss tradesecret or confidential commercial information relevant to PMA's for IOL's,surgical or diagnostic devices, contact lenses, or other ophthalmic devices.This portion of the meeting will be closed to permit discussion of thisinformation (5 U.S.C. 552b(c)(4)).<ITAG tagnum="84">Circulatory System Devices Panel</ITAG><T3>Date, time, and place. </T3>April 24, 1989, 8:30 a.m., Rm. 503A-529A,Hubert H. Humphrey Bldg., 200 Independence Ave. SW., Washington, DC.<T3>Type of meeting and contact person.</T3> Open public hearing, 8:30a.m. to 9:30 a.m., unless public participation does not last that long;open committee discussion, 9:30 a.m. to 2:30 p.m.; closed committee deliberations,2:30 p.m. to 4 p.m.; Keith Lusted, Center for Devices and RadiologicalHealth (HZF-450), Food and Drug Administration, 8757 Georgia Ave., SilverSpring, MD 20910, 301-427-7594.<T3>General function of the committee.</T3> The committee reviews and evaluatesavailable data on the safety and effectiveness of medical devices currentlyin use and makes recommendations for their regulation.<T3>Agenda_Open public hearing.</T3> Interested persons may present data,information, or views, orally or in writing, on issues pending before thecommittee. Those desiring to make formal presentations should notify thecontact person before April 14, 1989, and submit a brief statement of thegeneral nature of the evidence or arguments they wish to present, the namesand addresses of proposed participants, and an indication of the approximatetime required to make their comments.<T3>Open committee discussion.</T3> The committee will discuss premarketapproval applications (PMA's) for prosthetic heart valves, a percutaneoustransluminal coronary angioplasty catheter, and possibly a percutaneoustransluminal perfusion coronary angioplasty catheter.<T3>Closed committee deliberations.</T3> The committee will discuss tradesecret or confidential commercial information regarding the PMA's listedabove. This portion of the meeting will be closed to permit discussionof this information (5 U.S.C. 552b(c)(4)).<ITAG tagnum="84">Arthritis Advisory Committee</ITAG><T3>Date, time, and place.</T3> April 24 and April 25, 1989, 8:30 a.m.,Lister Hill Auditorium, National Library of Medicine, National Institutesof Health, Bldg. 38A, 8600 Rockville Pike, Bethesda, MD.<T3>Type of meeting and contact person.</T3> Open public hearing, April24, 1989, 8:40 a.m. to 9:40 a.m., unless public participation does notlast that long; open committee discussion, 9:40 a.m. to 4:30 p.m.; closedcommittee deliberations, April 25, 1989, 8:30 a.m. to 4 p.m.; David F.Hersey, Center for Drug Evaluation and Research (HFD-9), Food and DrugAdministration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4695.<T3>General function of the committee.</T3> The committee reviews and evaluatesavailable data on the safety and effectiveness of marketed and investigationalhuman drugs for use in arthritis and related diseases.<T3>Agenda_Open public hearing. </T3>Interested persons may present data,information, or views, orally or in writing, on issues pending before thecommittee. Those desiring to make formal presentations should notify thecontact person before April 7, 1989, and submit a brief statement on thegeneral nature of the evidence or arguments they wish to present, the namesand addresses of proposed participants, and an indication of the approximatetime required to make their comments.<T3>Open committee discussion.</T3> The committee will discuss: (1) changesin the investigational new drug (IND) and new drug application review processin the anti-inflammatory drug product group and possible new roles forthe advisory committee; and (2) a change in the policy for labeling analgesics.Seating capacity is limited and seating for the public will be on a firstcome, first serve, basis.<T3>Closed presentation of data.</T3> The committee will review trade secretor confidential commercial information relevant to IND 22,545. This portionof the meeting will be closed to permit discussion of this information(5 U.S.C. 552b(c)(4)).<ITAG tagnum="84">General and Plastic Surgery Devices Panel</ITAG><T3>Date, time, and place.</T3> April 27, 1989, 9 a.m., Auditorium, HubertH. Humphrey Bldg., 200 Independence Ave. SW., Washington, DC.<T3>Type of meeting and contact person.</T3> Open public hearing, 9 a.m.to 10 a.m., unless public participation does not last that long; open committeediscussion, 10 a.m. to 4 p.m.; closed committee deliberations, 4 p.m. to5 p.m.; Paul F. Tilton, Center for Devices and Radiological Health (HFZ-410),Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910,301-427-7238.<T3>General function of the committee.</T3> The committee reviews and evaluatesavailable data on the safety and effectiveness of devices and makes recommendationsfor their regulation.<T3>Agenda_Open public hearing. </T3>Interested persons may present data,information, or views, orally or in writing, on issues pending before thecommittee. Those desiring to make formal presentations should notify thecontact person before April 6, 1989, and submit a brief statement of thegeneral nature of the evidence or arguments they wish to present, the namesand addresses of proposed participants, and an indication of the approximatetime required to make their comments.<T3>Open committee discussion. </T3>The committee will discuss a premarketapproval application for a polypropylene surgical suture and a supplementalapplication for a gelatin matrix implant. The committee may also provideguidance on clinical trial design for electrical/magnetic stimulation devicesfor wound healing.<T3>Closed committee deliberations.</T3> The committee may discuss tradesecret or confidential commercial information regarding the manufactureof a polypropylene suture or a gelatin matrix implant. This portion ofthe meeting will be closed to permit discussion of this information (5U.S.C. 552b(c)(4)).Each public advisory committee meeting listed above may have as many asfour separable portions: (1) An open public hearing, (2) an open committeediscussion, (3) a closed presentation of data, and (4) a closed committeedeliberation. Every advisory committee meeting shall have an open publichearing portion. Whether or not it also includes any of the other threeportions will depend upon the specific meeting involved. The dates andtimes reserved for the separate portions of each committee meeting arelisted above.The open public hearing portion of each meeting shall be at least 1 hourlong unless public participation does not last that long. It is emphasized,however, that the 1 hour time limit for an open public hearing representsa minimum rather than a maximum time for public participation, and an openpublic hearing may last for whatever longer period the committee chairpersondetermines will facilitate the committee's work.Public hearings are subject ot FDA's guideline (Subpart C of 21 CFR Part10) concerning the policy and procedures for electronic media coverageof FDA's public administrative proceedings, including hearings before publicadvisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representativesof the electronic media may be permitted, subject to certain limitations,to videotape, film, or otherwise record FDA's public administrative proceedings,including presentations by participants.Meetings of advisory committees shall be conducted, insofar as is practical,in accordance with the agenda published in this <T4>Federal Register</T4> notice. Changes in the agenda will be announcedat the beginning of the open portion of a meeting.Any interested person who wishes to be assured of the right to make anoral presentation at the open public hearing portion of a meeting shallinform the contact person listed above, either orally or in writing, priorto the meeting. Any person attending the hearing who does not in advanceof the meeting request an opportunity to speak will be allowed to makean oral presentation at the hearing's conclusion, if time permits, at thechairperson's discretion.Persons interested in specific agenda items to be discussed in open sessionmay ascertain from the contact person the approximate time of discussion.Details on the agenda, questions to be addressed by the committee, anda current list of committee members are available from the contact personbefore and after the meeting. Transcripts of the open portion of the meetingwill be available from the Freedom of Information Office (HFI-35), Foodand Drug Administration, Rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857,approximately 15 working days after the meeting, at a cost of 10 centsper page. The transcript may be viewed at the Dockets Management Branch(HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville,MD 20857, approximately 15 working days after the meeting, between thehours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of theopen portion of the meeting will be available from the Freedom of InformationOffice (address above) beginning approximatley 90 days after the meeting.The Commissioner, with the concurrence of the Chief Counsel, has determinedfor the reasons stated that those portions of the advisory committee meetingsso designated in this notice shall be closed. The Federal Advisory CommitteeAct (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94-409),permits such closed advisory committee meetings in certain circumstances.Those portions of a meeting designated as closed, however, shall be closedfor the shortest possible time, consistent with the intent of the citedstatutes.The FACA, as amended, provides that a portion of a meeting may be closedwhere the matter for discussion involves a trade secret; commercial orfinancial information that is privileged or confidential; information ofa personal nature, disclosure of which would be a clearly unwarranted invasionof personal privacy; investigatory files compiled for law enforcement purposes;information the premature disclosure of which would be likely to significantlyfrustrate implementation of a proposed agency action; and information incertain other instances not generally relevant to FDA matters.Examples of portions of FDA advisory committee meetings that ordinarilymay be closed, where necessary and in accordance with FACA criteria, includethe review, discussion, and evaluation of drafts of regulations or guidelinesor similar preexisting internal agency documents, but only if their prematuredisclosure is likely to significantly frustrate implementation of proposedagency action; review of trade secrets and confidential commercial or financialinformation submitted to the agency; consideration of matters involvinginvestigatory files compiled for law enforcement purposes; and review ofmatters, such as personnel records or individual patient records, wheredisclosure would constitute a clearly unwarranted invasion of personalprivacy.Examples of portions of FDA advisory committee meetings that ordinarilyshall not be closed include the review, discussion, and evaluation of generalpreclinical and clinical test protocols and procedures for a class of drugsor devices; consideration of labeling requirements for a class of marketeddrugs or devices; review of data and information on specific investigationalor marketed drugs and devices that have previously been made public; presentationof any other data or information that is not exempt from public disclosurepursuant to the FACA, as amended; and, notably deliberative sessions toformulate advice and recommendations to the agency on matters that do notindependently justify closing. This notice is issued under section 10(a)(1) and (2) of the Federal AdvisoryCommittee Act (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), andFDA's regulations (21 CFR Part 14) on advisory committees.<ITAG tagnum="21">Dated: March 19, 1989.</ITAG><ITAG tagnum="6">Frank E. Young,</ITAG><ITAG tagnum="4">Commissioner of Food and Drugs.</ITAG><ITAG tagnum="40">[FR Doc. 89-6963 Filed 3-21-89; 11:10 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>